{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "LY3298176",
        "type": {
          "id": "8c421f76-3254-4ab6-abf6-fd7a6742f1b1",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "92826d3c-aa4a-48ce-ac9c-0c888ea14df8",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Insulin Glargine",
        "type": {
          "id": "db3df281-2ec0-4bae-acdb-94d733694e82",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "4e69f486-97da-494a-a0e8-bd0a02923000",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Basal insulin used as an active comparator, titrated following a treat-to-target algorithm.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Metformin",
        "type": {
          "id": "e87630aa-4adc-4bfe-84b6-aea2ab28d3df",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "930230c6-823b-466b-8be0-5c9b60e55899",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "SGLT-2 inhibitors",
        "type": {
          "id": "a0226d88-18bf-4085-8509-9d8fb9390e5a",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "676b99c9-727d-4766-b36b-4d5c84967175",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Sulfonylureas",
        "type": {
          "id": "66ee05a9-6e68-436e-a5a2-3e7222939419",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "83e56bda-954e-432c-a402-d9d9d24223ac",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral antihyperglycemic medication."
      },
      {
        "id": "int_6",
        "name": "GLP-1 receptor agonists",
        "type": {
          "id": "90010256-4ba7-4e11-ac7e-159171bbce0f",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "c7cae016-7d94-4126-a1e3-e97c30f7ee10",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_7",
        "name": "DPP-4 inhibitors",
        "type": {
          "id": "1087cfae-0b0e-484b-9ba5-e6d0e4448132",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "aafd72f0-f0fc-42e0-8e0f-4e1d6ce49113",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_8",
        "name": "Amylin analogs",
        "type": {
          "id": "68224e54-07b5-41b3-90f4-4810391cd4d8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3f827427-fbc0-46c6-900f-5389686a9dc0",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medication during the study."
      },
      {
        "id": "int_9",
        "name": "Weight loss medications",
        "type": {
          "id": "90bbd26c-a2fa-4bec-aae7-70bc1cee8aed",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "b02e3453-adbf-4f6f-904c-668d15cd8065",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited medications including Saxenda, Xenical, Meridia, etc., within 3 months prior to screening."
      },
      {
        "id": "int_10",
        "name": "Paracetamol/aspirin",
        "type": {
          "id": "66c1ffa1-e4be-48b9-9492-b73538a63df2",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a6f80ac1-15ac-4595-b270-e5a4d0fd19b5",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted over-the-counter drugs for symptomatic relief."
      },
      {
        "id": "int_11",
        "name": "Rescue therapy",
        "type": {
          "id": "a142e3ac-ee40-4fe9-aeb6-f6efe87b0621",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "6fc787ff-f8a3-4fe4-a91e-4517361ddad3",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "New glucose-lowering intervention for patients with severe, persistent hyperglycemia."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "LY3298176 prefilled syringe",
        "administrableDoseForm": {
          "id": "f1a5b674-2f01-4aeb-ad37-4349cd86e8c9",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "5d6d147a-d5d9-4276-b13a-042804b14beb",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "794ee84a-1356-4cb5-802d-26199f20d1e9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "prod_2",
        "name": "Insulin glargine prefilled pen",
        "administrableDoseForm": {
          "id": "4a989f4e-07df-418b-970c-f858857e192c",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "f598a968-c154-46cf-8d1c-330f13618156",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "9091a051-2e99-4356-9209-ee97d489108d",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "100 units/mL (implied by standard pen)",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Marketed product (e.g., Basaglar)"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "LY3298176 5 mg regimen",
        "instanceType": "Administration",
        "dose": "5 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks (titration starts at 2.5 mg for 4 weeks)"
      },
      {
        "id": "admin_2",
        "name": "LY3298176 10 mg regimen",
        "instanceType": "Administration",
        "dose": "10 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "id": "admin_3",
        "name": "LY3298176 15 mg regimen",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "id": "admin_4",
        "name": "Insulin glargine titration",
        "instanceType": "Administration",
        "dose": "Starting 10 IU/day, adjusted based on FBG",
        "doseFrequency": "once daily",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Up to 104 weeks"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "LY3298176",
        "instanceType": "Substance",
        "description": "GIP and GLP-1 receptor agonist; tirzepatide"
      },
      {
        "id": "sub_2",
        "name": "Insulin glargine",
        "instanceType": "Substance",
        "description": "Long-acting basal insulin analogue"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Investigational prefilled syringe",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "dev_2",
        "name": "Marketed prefilled pen",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company (Basaglar)"
      },
      {
        "id": "dev_3",
        "name": "Blood glucose meter",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 3
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "LY3298176",
        "role": "Investigational Product",
        "description": "A 39-amino acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors, administered once weekly."
      },
      {
        "name": "Insulin Glargine",
        "role": "Comparator",
        "description": "Basal insulin used as an active comparator, titrated following a treat-to-target algorithm."
      },
      {
        "name": "Metformin",
        "role": "Background Therapy",
        "description": "Oral antihyperglycemic medication; patients must be on a stable dose for at least 90 days prior to screening."
      },
      {
        "name": "SGLT-2 inhibitors",
        "role": "Background Therapy",
        "description": "Sodium-glucose co-transporter-2 inhibitors; oral antihyperglycemic medication."
      },
      {
        "name": "Sulfonylureas",
        "role": "Background Therapy",
        "description": "Oral antihyperglycemic medication."
      },
      {
        "name": "GLP-1 receptor agonists",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "DPP-4 inhibitors",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "Amylin analogs",
        "role": "Concomitant Medication",
        "description": "Prohibited medication during the study."
      },
      {
        "name": "Weight loss medications",
        "role": "Concomitant Medication",
        "description": "Prohibited medications including Saxenda, Xenical, Meridia, etc., within 3 months prior to screening."
      },
      {
        "name": "Paracetamol/aspirin",
        "role": "Concomitant Medication",
        "description": "Permitted over-the-counter drugs for symptomatic relief."
      },
      {
        "name": "Rescue therapy",
        "role": "Rescue Medication",
        "description": "New glucose-lowering intervention for patients with severe, persistent hyperglycemia."
      }
    ],
    "products": [
      {
        "name": "LY3298176 prefilled syringe",
        "doseForm": "Injection",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "name": "Insulin glargine prefilled pen",
        "doseForm": "Injection",
        "strength": "100 units/mL (implied by standard pen)",
        "manufacturer": "Marketed product (e.g., Basaglar)"
      }
    ],
    "substances": [
      {
        "name": "LY3298176",
        "description": "GIP and GLP-1 receptor agonist; tirzepatide"
      },
      {
        "name": "Insulin glargine",
        "description": "Long-acting basal insulin analogue"
      }
    ],
    "administrations": [
      {
        "name": "LY3298176 5 mg regimen",
        "dose": "5 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks (titration starts at 2.5 mg for 4 weeks)"
      },
      {
        "name": "LY3298176 10 mg regimen",
        "dose": "10 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "name": "LY3298176 15 mg regimen",
        "dose": "15 mg",
        "frequency": "once weekly",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks (titrated 2.5 mg every 4 weeks)"
      },
      {
        "name": "Insulin glargine titration",
        "dose": "Starting 10 IU/day, adjusted based on FBG",
        "frequency": "once daily",
        "route": "Subcutaneous",
        "duration": "Up to 104 weeks"
      }
    ],
    "devices": [
      {
        "name": "Investigational prefilled syringe",
        "manufacturer": "Eli Lilly and Company",
        "purpose": "Administration of LY3298176"
      },
      {
        "name": "Marketed prefilled pen",
        "manufacturer": "Eli Lilly and Company (Basaglar)",
        "purpose": "Administration of Insulin Glargine"
      },
      {
        "name": "Blood glucose meter",
        "manufacturer": "Not specified",
        "purpose": "Self-monitoring of blood glucose (SMBG)"
      }
    ]
  }
}